Tadeusz Robak
Impact in
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Hematology top 0.05%
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
Papers in
- Genetics 410
- Chronic Lymphocytic Leukemia Research 392
-
- Lymphoma Diagnosis and Treatment 222
- Co-authors
- Ewa Robak (49 shared papers)Piotr Smolewski (104 shared papers)Peter Hillmen (33 shared papers)Paweł Robak (54 shared papers)Barbara Eichhorst (12 shared papers)Michael Hallek (12 shared papers)Emili Montserrat (5 shared papers)Ewa Lech‐Marańda (46 shared papers)
- Journals
- Blood (113 papers)Journal of Clinical Oncology (38 papers)European Journal Of Haematology (19 papers)British Journal of Haematology (11 papers)Annals of Hematology (11 papers)
- Partner nations
- PolandUnited StatesUnited Kingdom
In The Last Decade
Tadeusz Robak
668 papers receiving 18.9k citations
Tadeusz Robak's Hit Papers
Peers
Comparison fields: 5 of 142
- Genetics 9.3k
- Hematology 5.2k
- Pathology and Forensic Medicine 6.3k
- Immunology 4.4k
- Oncology 4.1k
Countries citing papers authored by Tadeusz Robak
This map shows the geographic impact of Tadeusz Robak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadeusz Robak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadeusz Robak more than expected).
Fields of papers citing papers by Tadeusz Robak
This network shows the impact of papers produced by Tadeusz Robak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadeusz Robak. The network helps show where Tadeusz Robak may publish in the future.
Co-authors
The 25 scholars most cited alongside Tadeusz Robak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 706 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL Hit paper breakdown → | 2018 | 1002 |
| 2 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Hit paper breakdown → | 2011 | 663 |
| 3 | Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia Hit paper breakdown → | 2018 | 609 |
| 4 | Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression Hit paper breakdown → | 2007 | 506 |
| 5 | Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma Hit paper breakdown → | 2010 | 486 |
| 6 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Hit paper breakdown → | 2011 | 444 |
| 7 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 424 |
| 8 | 2010 | 414 | |
| 9 | 2007 | 409 | |
| 10 | 2010 | 359 | |
| 11 | Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome Hit paper breakdown → | 2018 | 356 |
| 12 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2020 | 348 |
| 13 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Hit paper breakdown → | 2019 | 320 |
| 14 | 2007 | 287 | |
| 15 | 2007 | 278 | |
| 16 | 2015 | 265 | |
| 17 | 2012 | 230 | |
| 18 | 2018 | 218 | |
| 19 | 2008 | 203 | |
| 20 | 2011 | 188 |
About Tadeusz Robak
Tadeusz Robak is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Immunology and Molecular Biology, having authored 706 papers that have together received 19.4k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (392 papers), Lymphoma Diagnosis and Treatment (222 papers), Acute Lymphoblastic Leukemia research (91 papers), Immunodeficiency and Autoimmune Disorders (90 papers), Chronic Myeloid Leukemia Treatments (68 papers), Acute Myeloid Leukemia Research (59 papers), Multiple Myeloma Research and Treatments (55 papers) and Monoclonal and Polyclonal Antibodies Research (54 papers). The work is most often cited by research in Genetics (9.3k citations), Hematology (5.2k citations), Pathology and Forensic Medicine (6.3k citations), Immunology (4.4k citations) and Oncology (4.1k citations). Tadeusz Robak has collaborated with scholars based in Poland, United States and United Kingdom. Frequent co-authors include Ewa Robak, Piotr Smolewski, Peter Hillmen, Paweł Robak, Barbara Eichhorst, Michael Hallek, Emili Montserrat, Ewa Lech‐Marańda, Agnieszka Wierzbowska and Anna Korycka. Their work appears in journals such as Blood, Journal of Clinical Oncology, European Journal Of Haematology, British Journal of Haematology and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.